Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValirx Share News (VAL)

Share Price Information for Valirx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.00
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 0.50 (6.25%)
Open: 8.25
High: 8.25
Low: 8.00
Yest. Close: 8.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

Tue, 26th Mar 2019 10:22

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.

Shares in ValiRx were up 16% at 0.62 pence on Tuesday morning.

ValiSeek is ValiRx's subsidiary joint venture, in which it owns a 55.5% majority stake, and was created in order to advance VAL401 as a treatment for late stage non-small cell lung cancer as well as other cancers.

A phase two clinical trial has already been completed and found that VAL401 improved overall survival in non-small cell lung cancer.

ValiSeek has now agreed letters of intent from two unnamed companies, one in Europe and one in the US, to advance VAL401 to its next clinical trial "on a co-financing basis".

ValiRx Chief Executive Satu Vainikka said: "I am delighted that ValiSeek has managed to secure a robust solution and strategy for the advancement of VAL401 and I believe that this outcome provides the best long-term value opportunity for ValiRx's investment in the ValiSeek project."

More News

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

24 Jul 20 17:23

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

23 Jul 20 18:02

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

16 Jul 20 15:57

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

6 Jul 20 18:19

ValiRx looks to build on portfolio of drug candidates

(Sharecast News) - Medicines developer ValiRx said on Monday that it was looking to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health.

6 Jul 20 09:31

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

1 Jul 20 13:10

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

16 Jun 20 13:58

ValiRx Delays Annual Results Amid Covid-19 Pandemic

ValiRx Delays Annual Results Amid Covid-19 Pandemic

8 Jun 20 15:39

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

2 Jun 20 12:57

ValiRx enters collaboration agreement for Covid-19 treatment

(Sharecast News) - Biotechnology oncology company ValiRx has entered into a collaboration agreement with Oncolytika and Black Cat Bio to explore the use of VAL201 in a combination treatment for patients suffering a hyperimmune response to Covid-19.

2 Jun 20 12:03

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

29 May 20 15:02

ValiRx offloads non-core IP to DDTech

(Sharecast News) - ValiRx has entered into a deed of assignment with Drug Discovery Technologies (DDTech) for the patents, materials and know-how associated with its non-core intellectual property 'FitBio' and 'TRAC', it announced on Friday.

29 May 20 12:59

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

27 May 20 14:20

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

7 May 20 14:45

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

4 May 20 16:18

Login to your account

Don't have an account? Click here to register.